Article

Fractioned radiotherapy safe and effective for optic nerve sheath meningiomas

Conformal fractionated radiotherapy should be the first choice of treatment for optic nerve sheath meningiomas, according to Silas Wang, MD.

Conformal fractionated radiotherapy should be the first choice of treatment for optic nerve sheath meningiomas, according to Silas Wang, MD.

"Optic nerve sheath meningiomas are rare and constitute only 1.3% of meningiomas," Dr. Wang said at the American Academy of Ophthalmology annual meeting.

Dr. Wang and colleagues from Yale University School of Medicine, New Haven, CT, used primary conformal fractioned radiotherapy (45.00 to 54.00 Gy in 25 to 29 fractions) in 16 patients, 14 of whom were women (average age, 45.1 years). Ninety-four percent of the patients had had vision loss. The mean follow-up was 45 months.

Dr. Wang reported that the visual acuity stabilized in 11 patients and the final visual acuity was 20/20 or better in nine patients. One patient had a progress decline in visual acuity to hand motion vision. There was an improvement of two or more lines of visual acuity in four patients. The visual fields improved by a mean of 3.2 decibels. In addition, the color vision stabilized. The delayed complications of the treatment included dry eye and hormonal changes. The results that Dr. Wang reported are consistent with those of a previous study.

"Conformal fractionated radiotherapy is effective in mild visual acuity loss," he concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.